Creo Medical Group PLC (AIM: CREO)

Market Cap	101.14M
Revenue (ttm)	30.80M
Net Income (ttm)	-21.70M
Shares Out	351.78M
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,236
Open	29.00
Previous Close	28.75
Day's Range	28.50 - 29.00
52-Week Range	28.00 - 50.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 9, 2024

About Creo Medical Group

Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; M...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2003
• Employees: 287
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: CREO

Financial Performance

In 2023, Creo Medical Group's revenue was 30.80 million, an increase of 13.24% compared to the previous year's 27.20 million. Losses were -21.70 million, -19.33% less than in 2022.